2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study

BACKGROUND: New CABP treatments with targeted activity and improved tolerability are needed. LEF, a novel pleuromutilin antibiotic that binds to a conserved region of the bacterial ribosome, is in development for IV or oral CABP treatment. This Phase 3 clinical study evaluated the efficacy of LEF vs...

Descripción completa

Detalles Bibliográficos
Autores principales: File, Thomas, Goldberg, Lisa, Paukner, Susanne, Das, Anita, Gelone, Steven P, Saviski, John, Sweeney, Carolyn, Seltzer, Elyse, Talbot, George H, Gasink, Leanne B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255284/
http://dx.doi.org/10.1093/ofid/ofy210.2039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255284/
http://dx.doi.org/10.1093/ofid/ofy210.2039

Ejemplares similares